Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.37 |
| ▸ | RELA | Q04206 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 5/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076642 | 0.80 | GAA (0.38) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL13479309 | 0.75 | GAA (0.39) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL15565008 | 0.73 | EPHX2 (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL15565005 | 0.73 | EPHX2 (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL29270785 | 0.73 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL26961952 | 0.73 | GAA (0.41) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL3484895 | 0.72 | EPHX2 (0.49) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL3484898 | 0.72 | EPHX2 (0.49) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL30675678 | 0.72 | GAA (0.40) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL29270699 | 0.72 | GAA (0.40) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20210371430-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371430-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | GAA 2916/4885NFKB1 648/4885NFKB2 999/4885 |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | GAA 2916/4885NFKB1 648/4885NFKB2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.